The Relative Strength (RS) Rating for Tandem Diabetes Care (TNDM) moved up into a higher percentile Monday, as it got a lift from 68 to 73.
X
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD’s proprietary RS Rating identifies technical performance by using a 1 (worst) to 99 (best) score that shows how a stock’s price performance over the last 52 weeks compares to other publicly traded companies.
Decades of market research reveals that the best stocks tend to have an 80 or better RS Rating in the early stages of their moves. See if Tandem Diabetes Care can continue to rebound and hit that benchmark.
Looking For Winning Stocks? Try This Simple Routine
Tandem Diabetes Care stock is working on a sloppy cup with handle with a 113.58 buy point. See if it can clear the breakout price in volume at least 40% higher than normal. Read „Looking For The Next Big Stock Market Winners? Start With These 3 Steps“ for more tips. Also, check out „Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks.“
Top and bottom line growth moved higher last quarter. Earnings were up 113%, compared to 0% in the prior report. Revenue increased from 44% to 58%.
The medical device firm earns the No. 31 rank among its peers in the Medical-Products industry group. Bio Rad Labs (BIOB) and Repligen (RGEN) are also among the group’s highest-rated stocks.
YOU MIGHT ALSO LIKE:
MarketSmith’s Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
[ad_2]
Source